Joshua A. Epstein joins SRx Health Solutions (SRXH) board as new director

Rhea-AI Filing Summary

SRx Health Solutions, Inc. reported that its Board of Directors appointed Joshua A. Epstein as a director effective October 1, 2025. He will serve until a successor is elected and qualified or until his resignation or removal.

Epstein brings over 20 years of operational, advisory, investing, and legal experience across energy, technology, healthcare, medical cannabis, blockchain, and gaming sectors. His background includes leadership roles in corporate development, private equity, cannabinoid and wellness manufacturing, and international medical cannabis, as well as earlier work as an M&A and securities attorney.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001471727 0001471727 2025-10-01 2025-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 1, 2025

SRx Health Solutions, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-40477		83-4284557
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

12400 Race Track Road

Tampa, Florida 33626

(Address of Principal Executive Offices) (Zip Code)

(Registrant’s Telephone Number, Including Area Code): (212) 896-1254

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value share		SRXH		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Joshua A. Epstein as a Director

On October 1, 2025, the Board of Directors (the “Board”) of SRx Health Solutions, Inc., a Delaware corporation (the “Company”) appointed Joshua A. Epstein, as a director of the Company, effective immediately, to serve in such capacity until a successor has been elected and qualified, or until his resignation or removal.

Mr. Epstein has over 20 years of operational, advisory and investing experience in the energy, technology, healthcare, medical cannabis, blockchain, and gaming sectors, including as an executive, investor, and attorney. Since December of 2024, Mr. Epstein has been the head of Corporate Development and on the Board of Managers for for Lisbon Valley Mining Co., overseeing all capital markets, M&A, partnership, and other transactional activities for the producing copper mine in Southeast Utah. Formerly, from March 2021 to November 2024, Mr. Epstein was a consultant to JJR Private Capital, a Florida and Toronto-based private equity firm founded in 2003. Previously, Mr. Epstein served as the CEO and Director of Socati Corp., a vertically integrated manufacturer of ingredients and consumer products for global cannabinoid and wellness markets. Prior to Socati, Mr. Epstein served as President and COO of Nuuvera Inc., an international wellness and medical cannabis company founded in 2016 that later listed on the Toronto Stock Exchange–V and sold to Tilray Inc. (NASDAQ: TLRY) (formerly Aphria Inc.) in 2018. Mr. Epstein was previously a Partner with FastForward Innovations Ltd., an early-stage venture capital firm where he oversaw investments and divestitures of the firm’s portfolio companies in the United States, Canada, the United Kingdom, Germany, Israel and China. Mr. Epstein began his career as an attorney with the international law firm Baker Botts, LLP, where his practice focused on mergers and acquisitions, venture capital and securities offerings. Mr. Epstein holds a B.A (English, Honors Program) and B.B.A. (Finance) from the University of Texas, a JD from the University of Texas School of Law, where he graduated with Honors and as a member of the Texas Law Review, and an MBA from the Acton School of Business in Austin, Texas, where he was Valedictorian of his class.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated October 1, 2025.
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SRx Health Solutions, Inc.
	By:	/s/ Carolina Martinez
	Name:	Carolina Martinez
	Title:	Chief Financial Officer

October 6, 2025

FAQ

What did SRx Health Solutions, Inc. (SRXH) announce in this 8-K?

SRx Health Solutions, Inc. announced that its Board appointed Joshua A. Epstein as a director of the company, effective October 1, 2025.

Who is Joshua A. Epstein, the new director at SRx Health Solutions (SRXH)?

Joshua A. Epstein has over 20 years of experience in operational, advisory, investing, and legal roles across sectors including energy, technology, healthcare, medical cannabis, blockchain, and gaming.

How long will Joshua A. Epstein serve on the SRx Health Solutions Board?

Joshua A. Epstein will serve as a director until a successor is elected and qualified, or until his resignation or removal, as stated in the report.

What prior leadership roles has Joshua A. Epstein held before joining SRx Health Solutions?

Epstein has served as head of Corporate Development and on the Board of Managers for Lisbon Valley Mining Co., consulted for JJR Private Capital, and was previously CEO and Director of Socati Corp. and President and COO of Nuuvera Inc.

Does the 8-K filing include any financial statements for SRx Health Solutions (SRXH)?

The filing lists an exhibit for a press release dated October 1, 2025 and a cover page data file, but the main text focuses on the appointment of Joshua A. Epstein as a director.

Who signed the SRx Health Solutions (SRXH) 8-K related to the new director appointment?

The report was signed on behalf of SRx Health Solutions, Inc. by Carolina Martinez, the company’s Chief Financial Officer.